CSL LIMITED
-
AUD
(-)
- End-of-day data - Australia Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | CSL |
| ISIN: | AU000000CSL8 |
CSL LIMITED news, videos and press releases
For more news please use our advanced search feature.
CSL LIMITED - More news...
CSL LIMITED - More news...
- 02/20/2025 - 14:13 CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
- 02/14/2025 - 13:30 European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- 02/14/2025 - 13:00 European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
- 02/13/2025 - 12:00 European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- 02/07/2025 - 14:12 CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
- 02/06/2025 - 02:00 CSL ANNOUNCES THE ACQUISITION OF EDGECONNECT
- 12/13/2024 - 15:38 CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
- 12/09/2024 - 13:00 CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
- 10/18/2024 - 12:30 New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
- 10/17/2024 - 06:30 CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- 10/16/2024 - 13:00 CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
- 10/04/2024 - 16:30 CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
- 10/01/2024 - 15:00 CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
- 09/25/2024 - 20:30 CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
- 09/24/2024 - 07:30 Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
- 09/13/2024 - 12:15 Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
- 07/09/2024 - 13:00 CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
- 07/04/2024 - 07:00 CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
- 06/20/2024 - 08:00 CAREIUM & CSL EXTEND THEIR PARTNERSHIP WITH THE LAUNCH OF rSIM® TECHNOLOGY
- 05/30/2024 - 13:00 CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
- 05/20/2024 - 12:30 Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
- 05/02/2024 - 13:30 Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
- 05/02/2024 - 12:12 CRITICAL IOT CONNECTIVITY EXPERTS, CSL, ARE DELIGHTED TO ANNOUNCE THE APPOINTMENT OF GREVILLE COE AS CHIEF COMMERCIAL OFFICER
- 04/24/2024 - 07:00 CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- 04/08/2024 - 11:00 Peak and CSL Join Forces in Europe as Peak CSL Group
- 03/19/2024 - 11:00 Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- 03/06/2024 - 14:00 CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
- 02/23/2024 - 07:00 CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
- 02/13/2024 - 06:21 Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
- 02/13/2024 - 04:31 Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
